Eugen F Mesaros, Benjamin J Dugan, Min Gao, Muhammad Sheraz, Kayleigh McGovern-Gooch, Fran Xu, Kristi Yi Fan, Duyan Nguyen, Steven G Kultgen, Aaron Lindstrom, Kim Stever, Breanna Tercero, Randall J Binder, Fei Liu, Holly M Micolochick Steuer, Nagraj Mani, Troy O Harasym, Emily P Thi, Andrea Cuconati, Bruce D Dorsey, Andrew G Cole, Angela M Lam, Michael J Sofia
The recent COVID-19 pandemic underscored the limitations of currently available direct-acting antiviral treatments against acute respiratory RNA-viral infections and stimulated major research initiatives targeting anticoronavirus agents. Two novel nsp5 protease (MPro) inhibitors have been approved, nirmatrelvir and ensitrelvir, along with two existing nucleos(t)ide analogues repurposed as nsp12 polymerase inhibitors, remdesivir and molnupiravir, but a need still exists for therapies with improved potency and systemic exposure with oral dosing, better metabolic stability, and reduced resistance and toxicity risks...
April 23, 2024: ACS Infectious Diseases